UCL Cancer Institute

What UCL Cancer Institute does

University College London (UCL) is a public research university founded in 1826 as London's first university, now operating across two main campuses in London: the central Bloomsbury campus on Gower Street and the UCL East campus at Queen Elizabeth Olympic Park in Stratford. The institution serves a global community drawn from more than 150 countries, delivering over 400 undergraduate courses, more than 700 graduate courses, and extensive research degree programs across multiple faculties. UCL's research output includes high-impact biomedical work such as CAR T-cell therapy clinical trials (developed via spinout Autolus Therapeutics) and gene testing advances for breast cancer treatment stratification.

The university operates a substantial digital and physical infrastructure to support its academic and research mission. Core technology includes a central Drupal-based web platform, Moodle LMS for course delivery, Panopto for video, OneDrive and SharePoint for collaboration, AWS with F5 BIG-IP load balancing, and Cloudflare CDN. Specialized systems include the UCL Data Safe Haven for secure research data handling and a LogicGate-based DPIA workflow for data protection compliance. Digital Accessibility Hubs at Bloomsbury and UCL East provide assistive technology and accessibility training for students and staff with disabilities. The institution's revenue model combines publicly funded higher education delivery with some fee-based programs, short courses, summer schools, and study abroad offerings; specific tuition and pricing are not disclosed.

UCL's strategic positioning rests on a 200-year heritage, top-ten global rankings (joint 8th in QS World University Rankings 2027, 7th in U.S. News Best Global Universities 2025-2026), and leadership in sustainability (1st in UK, 3rd globally in QS Sustainability Rankings 2026). The institution maintains extensive regional partnerships across London's knowledge economy, including with Knowledge Quarter, London Medicine, Camden Council, Islington Council, Newham Council, and East Bank Development, supporting its role as both an academic and civic institution. Note: the provided source material describes UCL as a whole rather than the UCL Cancer Institute specifically; no cancer-institute-specific products, headcount, revenue, or research portfolio were disclosed in the input data.

Name

UCL Cancer Institute

Legal name

University College London

Website

https://ucl.ac.uk

Company type

Private

Founded year

1826

Operating status

Operating

Short description

UCL Cancer Institute is a research unit within University College London, a public research university founded in 1826. The parent institution serves a global student community across 400+ undergraduate and 700+ graduate courses, with research strength in biomedical sciences including cancer-related work.

Ownership category

akta.pro rank

Product category

Higher Education and Research

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC)

akta.pro secondary industries

International & Global Research Universities (Multi-Campus/International Footprint) (EDAHABAI), STEM-Focused Public Research Universities (EDAHAAAE)

Keywords

• Cancer research
• Clinical trials
• Translational medicine
• Oncology research
• Biomedical research

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Distribution channels5 records

Marketing channels6 records

Core offering

UCL Cancer Institute is the cancer research arm of University College London, conducting fundamental and translational cancer research alongside clinical trials and therapeutic development. Its outputs include contributions to CAR T-cell therapy development through UCL spinout Autolus Therapeutics and gene testing research enabling breast cancer patients to safely avoid unnecessary chemotherapy. The institute operates within UCL's broader higher education and research framework, leveraging UCL's research infrastructure, clinical partnerships with UCLH, and access to a global academic community.

Product overview

No specific product or service information for UCL Cancer Institute was found in the provided sources. The sources contain general information about University College London (UCL) as an institution, including its academic programs, research activities, accessibility services, data protection policies, and digital services. There is no dedicated UCL Cancer Institute product portfolio, platform, or named service offerings identified in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• Undergraduate Degree Programs

Quantifiable outcome

• CAR T-cell therapy developed by UCL spinout Autolus Therapeutics shows early promise in treating severe lupus
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered core and major.

• Autolus TherapeuticscoreStrategic or Co-development PartnerUCL spinout company developing CAR T-cell therapy. Clinical trial led by UCL and UCLH showing early promise for treatment-resistant lupus. The therapy represents a collaboration between academic research and commercial biotech development.
• Camden CouncilmajorStrategic or Co-development PartnerUCL has a Memorandum of Understanding with Camden Council for London-focused engagement and community partnerships.
• London HighercoreStrategic or Co-development PartnerRegional higher education association representing over 40 London institutions. UCL London Office previously collaborated through this association.
• London MedicinecoreStrategic or Co-development PartnerGroup representing London's five university medical schools for collaborative medical education and research.
• Islington CouncilmajorStrategic or Co-development PartnerPartnership with Islington Council for London Office external partnerships and community engagement.
• British LandmajorStrategic or Co-development PartnerCorporate connection through London Office partnerships for real estate and development collaboration.
• BusinessLDNmajorStrategic or Co-development PartnerLondon business organization partnership for corporate connections and economic development.
• Knowledge QuartercoreStrategic or Co-development PartnerKnowledge Quarter partnership for research and innovation collaboration in the Kings Cross area.
• Newham CouncilmajorStrategic or Co-development PartnerPartnership with Newham Council focusing on fostering connections in East London and UCL East campus activities.
• East Bank Development (Queen Elizabeth Olympic Park)majorStrategic or Co-development PartnerPartnership with East Bank development on Queen Elizabeth Olympic Park for UCL East campus integration and community initiatives.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• ETH Zurich: European public research university with comparable STEM focus and global ranking band; relevant comparator for international research talent flow and continental European positioning.
• Stanford University: US private research university with industry-tied commercialization and AMC-scale biomedical research; benchmarks UCL's translational medicine and spinout model in a global context.
• King's College London: Another central London public research university with major health/AMCs and humanities faculties; competes directly with UCL for London students, research grants, and AMC-linked partnerships.
• University of Cambridge: UK public research university with parallel strengths in science, medicine, and commercializing research through Cambridge Enterprise; competes head-to-head with UCL in rankings and faculty recruitment.
• University of Oxford: UK public research university of comparable global standing, competing with UCL for top international applicants, research council funding, and spinout formation in biotech and life sciences.
• University of Edinburgh: Major UK public research university with comparable breadth of disciplines and a medical school; operates in the same Russell Group tier and competes for research council and international student share.
• Massachusetts Institute of Technology: Global top-ten STEM-focused research university with extensive biotech spinout activity; aspirational peer in the same QS top-10 band and a benchmark for commercialization of academic research.
• Imperial College London: London-based public research university with a strong STEM and medical school focus; the closest direct comparator to UCL given shared geography, AMC status, and similar global ranking band.
• Harvard University: Global top-ranked research university with the broadest peer comparison in scale, AMC integration, and international student share; defines the upper bound of UCL's competitive set.

Broad incumbents

• London School of Economics and Political Science: London-based University of London member institution that overlaps with UCL in social sciences and policy research; competes for the same London student pool and global reputation tier but lacks UCL's STEM/medical breadth.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ucl
• YouTubeyoutube.com/ucltv
• Facebookfacebook.com/uclofficial
• LinkedInlinkedin.com/company/university-college-london
• Instagraminstagram.com/ucl
• TikToktiktok.com/@uclofficial

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCL Cancer Institute